Fig. 4

Effect of oxaliplatin on cold hypersensitivity after TRPA1 knockdown in the acetone spray test and water spray test. Intrathecal administration of TRPA1 AS-ODN prevents cold hypersensitivity induced by oxaliplatin (6 mg/kg, i.p.) as seen with the acetone spray test, but not the water spray test. The water spray test (22 °C) and acetone spray test at days 1, 2, 4, and 7 after oxaliplatin were measured in TRPA1 AS-ODN and TRPA1 MM-ODN treatment groups. a Histograms show the mean ± SEM of cold hypersensitivity at days 0 (before administration), 1, 2, 4, and 7 after oxaliplatin administration in the water spray test (22 °C). b Histograms show cold hypersensitivity at days 0 (before administration), 1, 2, 4, and 7 after oxaliplatin administration in the acetone spray test. Data are the mean ± SEM. n = 4 for oxaliplatin administration. *P < 0.05, **P < 0.01 versus TRPA1 MM-ODN treatment groups. c The TRPA1 AS-ODN was effective at reducing TRPA1 protein expression. TRPA1 and β-actin protein in DRGs at day 2 after oxaliplatin administration (6 mg/kg, i.p.) was measured. TRPA1 expression was normalized to β-actin expression. Histograms show the relative amount of TRPA1 protein in oxaliplatin (6 mg/kg, i.p.)-treated rats. The western blot shows representative data. Data are the mean ± SEM. n = 4 for oxaliplatin administration. *P < 0.05 versus TRPA1 MM-ODN treatment groups